Upon failure of a TNFI, what is the evidence and rationale for switching to an agent with an alternative MOA, including an IL-6 inhibitor or T-cell co-modulating agent?

Upon failure of a TNFI, what is the evidence and rationale for switching to an agent with an alternative MOA, including an IL-6 inhibitor or T-cell co-modulating agent?

Upon failure of a TNFI, what is the evidence and rationale for switching to an agent with an alternative MOA, including an IL-6 inhibitor or T-cell co-modulating agent?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Eric Ruderman, MD

Eric Ruderman, MD

Professor of Medicine
Division of Rheumatology
Northwestern University, Feinberg School of Medicine
Chicago, Illinois